New Findings about IBD Patients having COVID-19

New Findings about IBD Patients having COVID-19

Published: 08-Jul-2020 | Published By: Market Research Store

In the clinical course of COVID-19, researchers from the University of North Carolina School of Medicine and Icahn School of Medicine at Mount Sinai have studied the risk factors that are associated by studying a large number of patients having Inflammatory Bowel Disease (IBD) with the help of an international registry. This forthcoming study is to be published in the journal Gastroenterology.

The time COVID-19 cases were rapidly increasing in the US the researchers came together to form international registry of the people who were suffering from inflammatory bowel disease and COVID-19. SECURE-IBD (Surveillance Epidemiology of Coronavirus under Research Exclusion for Inflammatory Bowel Disease) is the registry and till date has made inclusion from 33 nations of 528 patients.

The co-author of the study Erica Brenner, MD, commented that the purpose of establishing the registry was to help distinguish how COVID-19 affected the patients’ who were having inflammatory bowel disease. The evaluations were made and there were considerations taken about any association between the clinical uniqueness, demographics, and the treatments.
With the help of their study the researchers were able to conclude that corticosteroids, comorbidities, and increasing age are some of factors that are connected with the IBD patients’ suffering from severe conditions of COVID-19. Through this study a casual connection was found but there were no hard core establishments about the fact. In particular, there were no associations found in terms of TNF antagonists and COVID-19.

Ryan Ungaro, MD, gastroenterologist with Mount Sinai Hospital's Feinstein IBD Center, the co-author of the study said that the key findings of the study is that the IBD patients’ should reduce steroid-sparing treatments,  which will be quite helpful at this time of the pandemic. No association of TNF antagonist treatment and COVID-19 is a relief as this is the most approved biologic treatment for IBD and increased number of patients have requirement of this therapy.

Market Research Store has published the report on the global inflammatory bowel disease market. The report highlights that the market will gain rapid growth in the coming years owing to the rise in the number of people suffering from inflammatory bowel diseases.